GSK and Innoviva have published data from a study in which Anoro Ellipta umeclidinium/vilanterol demonstrated superior lung function improvement in COPD patients compared to Stiolto Respimat tiotropium/olodaterol. The data were published in Advances in Therapy and at the 2017 CHEST meeting.
The study, which enrolled 236 COPD patients, measured trough FEV1 at 8 weeks and found a treatment effect of 180mL for Anoro Ellipta compared to 128mL for Stiolto Respimat. The tolerability and safety profiles for both inhalers were comparable.
GSK Senior VP, Head Global Respiratory Eric Dube commented, “Improving lung function is a clear goal in patients with COPD. The challenge for healthcare professionals to date has been the lack of differentiation within the LAMA/LABA class. That is why we have conducted this study, as the first in-class head-to-head comparison of two fixed-dose once-daily LAMA/LABAs. These data demonstrate that UMEC/VI (Anoro) provides superior lung function improvements to the comparator TIO/OLO.”
Innoviva CEO Michael Aguiar said, “COPD is a progressive, chronic disease, affecting over 300 million people worldwide. We believe that these data clearly demonstrate the benefit of Anoro Ellipta versus Stiolto Respimat for symptomatic, moderate COPD patients whose primary therapeutic need is additional bronchodilatation and we are very pleased with these results.”
Read the GSK/Innoviva press release.
